Marion Wealth Management Acquires 837 Shares of iShares Biotechnology ETF $IBB

Marion Wealth Management lifted its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 4.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 21,057 shares of the financial services provider’s stock after purchasing an additional 837 shares during the period. Marion Wealth Management owned 0.05% of iShares Biotechnology ETF worth $2,664,000 as of its most recent filing with the SEC.

Several other hedge funds have also made changes to their positions in the stock. Citigroup Inc. lifted its stake in shares of iShares Biotechnology ETF by 88.5% in the first quarter. Citigroup Inc. now owns 3,208,144 shares of the financial services provider’s stock valued at $410,322,000 after buying an additional 1,505,976 shares during the period. Commonwealth Equity Services LLC lifted its stake in shares of iShares Biotechnology ETF by 12.0% in the first quarter. Commonwealth Equity Services LLC now owns 194,516 shares of the financial services provider’s stock valued at $24,879,000 after buying an additional 20,915 shares during the period. Jones Financial Companies Lllp lifted its stake in shares of iShares Biotechnology ETF by 763.3% in the first quarter. Jones Financial Companies Lllp now owns 151,265 shares of the financial services provider’s stock valued at $19,347,000 after buying an additional 133,744 shares during the period. Generali Investments CEE investicni spolecnost a.s. lifted its stake in shares of iShares Biotechnology ETF by 35.0% in the second quarter. Generali Investments CEE investicni spolecnost a.s. now owns 116,115 shares of the financial services provider’s stock valued at $14,690,000 after buying an additional 30,115 shares during the period. Finally, MAI Capital Management lifted its stake in shares of iShares Biotechnology ETF by 4.2% in the first quarter. MAI Capital Management now owns 98,158 shares of the financial services provider’s stock valued at $12,554,000 after buying an additional 3,923 shares during the period. Institutional investors own 62.45% of the company’s stock.

iShares Biotechnology ETF Trading Down 1.2%

NASDAQ IBB opened at $157.46 on Tuesday. The firm has a 50-day simple moving average of $147.19 and a 200 day simple moving average of $134.68. iShares Biotechnology ETF has a twelve month low of $107.43 and a twelve month high of $159.79.

iShares Biotechnology ETF Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, September 19th. Investors of record on Tuesday, September 16th were paid a $0.0828 dividend. This represents a $0.33 annualized dividend and a dividend yield of 0.2%. The ex-dividend date was Tuesday, September 16th.

iShares Biotechnology ETF Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.